Gi-Hoon Nam

Dr. Gi-Hoon Nam is the founder and Chief Executive Officer of SHIFTBIO, a delivery platform company that engineers cell-derived natural nanoparticles (NNPs) into programmable vehicles for RNA, ASO, and protein therapeutics. He holds an MD/PhD background in nanomedicine and tumor immunology, and serves as a Principal Investigator at Korea University College of Medicine. His scientific contributions span membrane-engineered vesicle scaffolds, brain-penetrant delivery design, and structure-prediction-driven platform development. At SHIFTBIO he leads the company’s NNP Trinity platform (NSM Scaffold, NNP Design AI, and a validated 3D bioreactor manufacturing process) and its two delivery lines, B-NNP for CNS indications and I-NNP for inflammation, fibrosis, and oncology. The company’s lead immunology assets, SBI-101 and SBI-102, have received Orphan Drug Designation and completed a Pre-IND meeting, with IND submission and Phase 1 entry on track.